language_icon
EN
HI

Akums Drugs & Pharmaceuticals Share price

AKUMS

521.35

6.40 (1.24%)
NSE
BSE
Last updated on 21 May, 2026 | 15:55 IST
Today's High

527.40

Today's Low

509.15

52 Week Low

409.30

52 Week High

622.95

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Akums Drugs & Pharmaceuticals Chart

Akums Drugs & Pharmaceuticals Share Key Metrics

Volume
2.21 L
Market Cap
8205.74 CR
LTQ@LTP
80@521.35
ATP
519.86
Var Margin
17.27 %
Circuit Range
463.5-566.4
Delivery %
66.79 %
Value
11.50 CR
ASM/GSM
No
Market Lot
1

Summary

Akums Drugs & Pharmaceuticals share price is ₹521.35 as of 22 May, 2026. The stock Akums Drugs & Pharmaceuticals intraday movement has stayed between ₹509.15 and ₹527.40, while on a 52-week basis,Akums Drugs & Pharmaceuticals price 52 week high is ₹622.95 & its 52 week low is ₹409.30.
In terms of trading activity, Akums Drugs & Pharmaceuticals has recorded a volume of 221302 shares, The Akums Drugs & Pharmaceuticals has a market cap of ₹157393988 CR. The stock’s Average Traded Price (ATP) stands at ₹519.86, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 80 @ ₹521.35.
Akums Drugs & Pharmaceuticals operates within a circuit range of ₹463.50 – ₹566.40, with a Value of ₹11.50 CR. The Delivery Percentage for the day is 66.79%. Additionally, Akums Drugs & Pharmaceuticals currently falls under the No framework, and trades with a market lot size of 1.

Akums Drugs & Pharmaceuticals Fundamentals

View More
P/E Ratio

31.72

P/B Ratio

2.44

Div. Yield

0.58

Sector P/E

71.81

Sector P/B

3.44

Sec. Div. Yield

0.55

Akums Drugs & Pharmaceuticals Resistance and Support

Pivot 516.32

Resistance

First Resistance

522.29

Second Resistance

529.62

Third Resistance

535.59

Support

First Support

508.99

Second Support

503.02

Third Support

495.69

Akums Drugs & Pharmaceuticals Shareholding Pattern

View More
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

75.26%

Mutual Fund

10.95%

Insurance

0.6%

Foreign Institutional Investors

1.38%

Domestic Institutional Investors

2.79%

Retail

9.02%

Others

0%

Total Promoters
MAR '26
75.26%

Akums Drugs & Pharmaceuticals Corporate Actions

DateAgenda
2026-05-14Audited Results & Final Dividend
2026-02-13Quarterly Results
2025-11-13Quarterly Results
2025-08-08Quarterly Results
2025-05-26Audited Results
2025-02-06Quarterly Results

Akums Drugs & Pharmaceuticals News

Akums Drugs and Pharmaceuticals Ltd - 544222 - Receipt Of Assessment Order(S) From Income Tax Department

Akums Drugs & Pharma and its subsidiary Akumentis Healthcare Ltd. have received assessment orders from the Income Tax Department for a total demand of Rs.133.75 crore. The company believes the demand is not sustainable and plans to appeal the orders.
May 20 2026 19:05:00

Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Akums Drugs & Pharma has made available the audio recording of its investors/analysts conference call held on May 18, 2026. The call discussed the unaudited financial results for Q4 FY26 and audited results for FY26. The transcript will be uploaded later.
May 18 2026 17:05:00

Akums Drugs and Pharmaceuticals Ltd - 544222 - Update On Disruption In Operations At Some Of The Manufacturing Sites At Haridwar

Akums Drugs & Pharma has fully resumed manufacturing operations at its Haridwar sites, effective May 18, 2026. A four-day disruption had resulted in a delayed supply of approximately Rs.20 crore, which the company expects to recover.
May 18 2026 12:05:00

Akums Drugs and Pharmaceuticals Ltd - 544222 - Intimation Of Disruption In Operations At Some Of The Manufacturing Sites At Haridwar

Akums Drugs & Pharma reported temporary disruption of manufacturing operations at some Haridwar sites due to labour unrest on May 14, 2026. The company is actively working with authorities and workers to normalize operations.
May 14 2026 16:05:00

Akums Drugs and Pharmaceuticals Ltd - 544222 - Corporate Action-Board approves Dividend

Akums Drugs & Pharma recommended a total dividend of ₹3.00 per equity share for FY26, comprising a final dividend of ₹1.00 and a special dividend of ₹2.00. The record date is July 3, 2026.
May 14 2026 14:05:00

Akums Drugs and Pharmaceuticals Ltd - 544222 - Recommendation Of Final Cum Special Dividend

Akums Drugs & Pharma received show cause notices from the Income Tax Department for disallowance of expenses, stemming from a search and seizure operation in January 2025. This matter was noted by the auditor as an 'Emphasis of Matter', indicating potential unquantified financial impact.
May 14 2026 13:05:00

Akums Drugs and Pharmaceuticals Ltd - 544222 - Board Meeting Outcome for Outcome Of Board Meeting For Financial Results

Akums Drugs & Pharma Board approved FY26 consolidated financial results, reporting ₹4,487.74 crore revenue (up 7.6% YoY) and ₹256.40 crore net profit (down 25.4% YoY). A total dividend of ₹3.00 per share was recommended, with July 03, 2026, as the record date. The board also appointed new internal auditors and confirmed changes in senior HR management.
May 14 2026 13:05:00

Akums Drugs and Pharmaceuticals Ltd - 544222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

Akums Drugs will conduct an analyst and investor conference call on May 18, 2026, to discuss its Q4 and full-year FY26 financial results. The virtual call will feature presentations from key management personnel, including the MDs, CFO, and Head Strategy.
May 12 2026 20:05:00

Akums Drugs and Pharmaceuticals Ltd - 544222 - Board Meeting Intimation for Board Meeting Intimation

Akums Drugs & Pharma's Board of Directors will convene on May 14, 2026, to consider and approve the audited financial results for Q4 FY26 and the full financial year. Additionally, the board will recommend a dividend, if any, for FY26.
May 11 2026 23:05:00

Akums Drugs and Pharmaceuticals Ltd - 544222 - Execution Of Lease Deed

Akums Drugs' wholly-owned subsidiary, Pure and Cure Healthcare, acquired an industrial plot of approximately 4050 Sq. Mtrs in Haridwar, Uttarakhand. This plot is adjacent to the existing manufacturing facility and will support the subsidiary's business operations.
Apr 29 2026 17:04:00
Read More

About Akums Drugs & Pharmaceuticals

NSE : 24715  
BSE : 544222  
ISIN : INE09XN01023  

Our Company was incorporated as a public limited company under the Companies Act 1956 as ‘Akums Drugs and Pharmaceuticals Limited’ pursuant to a certificate of incorporation dated April 19 2004 issued by the RoC. Our Company received a certificate for commencement of business issued by the RoC dated May 13 2004.Major Events and Milestones:2004-Incorporation of the Company-Established first plant for oral dosage commissioned at 19 20 21 sector 6A Haridwar Uttarakhand2007-Established dedicated manufacturing site for oral liquid dosage at 22 Sector 6A Sidcul Haridwar Uttarakhand and sterile products at 2345 Sector 6B SIDCUL Haridwar Uttarakhand2009-Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals2010-Dedicated a facility for hormones at 48 Sector 6A SIDCUL Haridwar Uttarakhand-Dedicated a facility for cosmetics and dermatology at 47 Sector 6A SIDCUL Haridwar Uttarakhand-Incorporated Akumentis Healthcare Limited to venture into branded formulations2011-Innovated bi-layered sustained release tablets for the first time2012-Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities2013-Innovated tablet-in-tablet sustained release tablets for the first time-Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities-Expanded into the African market2015-Expanded into the Asian market-Established research and development laboratory in Mumbai Maharashtra to venture into regulated market2016-Maxcure Nutravedics Limited received US-NSF certification2019-Investment by Ruby QC Investment Holdings Pte. Ltd. in our Company to become a minority shareholder2021-Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs-Acquisition of a facility at Kotdwar Uttarakhand by Akums Healthcare Limited2022-Plant at 19 20 21 Sector 6A SIDCUL Haridwar Uttarakhand and plant at 2 3 45 Sector 6B SIDCUL Haridwar Uttarakhand accredited European Union-Good Manufacturing Practices qualifying for exports to European markets-Acquisition of a facility in Haridwar Uttarakhand by Akums Healthcare Limited and a facility in Baddi Himachal Pradesh by Pure and Cure Healthcare Private Limited2023-Acquisition of another facility in Baddi Himachal Pradesh by Pure and Cure Healthcare Private Limited-Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited

Read More

Akums Drugs & Pharmaceuticals Management

NamePosition
Sanjeev JainManaging Director
Sandeep JainManaging Director
View More

Akums Drugs & Pharmaceuticals FAQs

The Buying Price of Akums Drugs & Pharmaceuticals share is 521.35 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Akums Drugs & Pharmaceuticals stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Akums Drugs & Pharmaceuticals, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Akums Drugs & Pharmaceuticals shares is 31.72. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Akums Drugs & Pharmaceuticals shares is 2.44. Useful to assess the stock's value relative to its book value.

To assess Akums Drugs & Pharmaceuticals’s valuation compare Sector P/E, P/B which are 71.81 & 3.44 with sector averages, along with growth rates and financial metrics.

The Market Cap of Akums Drugs & Pharmaceuticals is 8205.74 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Akums Drugs & Pharmaceuticals share price is 622.95 & 409.30. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Akums Drugs & Pharmaceuticals belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost